Preliminary research indicates that use of nitroglycerin ointment among postmenopausal women for 2 years was associated with a modest increase in bone mineral density and decrease in bone resorption (loss), according to a study in the February 23 issue of JAMA.
"The number of osteoporotic fractures is increasing worldwide as populations age. An inexpensive and widely available treatment may help limit this increase," the authors write. "Nitroglycerin stimulates bone formation and inhibits bone resorption, is inexpensive, and is widely available. Its effects on bone density, bone structure, and bone strength are unknown." Nitroglycerin is used medically as a vasodilator (a drug that causes dilation of blood vessels) to treat heart conditions, such as angina and chronic heart failure.
Sophie A. Jamal, M.D., Ph.D., of the Women's College Research Institute and University of Toronto, Canada, and colleagues tested the efficacy of once-daily nitroglycerin ointment to increase bone mineral density (BMD) at the lumbar spine, femoral (bone in the leg that extends from the hip to the knee) neck and hip. The placebo-controlled randomized trial was conducted from November 2005 to March 2010 and included 243 postmenopausal women. The participants were randomized to nitroglycerin ointment (15 mg/d; n = 126) or placebo (n = 117), applied at bedtime to the upper arm for 2 years.
The researchers found that compared with placebo, women randomized to the nitroglycerin group had significant increases in areal (an area) BMD at the lumbar spine (6.7 percent), total hip (6.2 percent), and femoral neck (7.0 percent) at 24 months. Nitroglycerin users also had increases in certain measures of BMD and bone strength of the radius and tibia. Additionally, compared with placebo, treatment with nitroglycerin was significantly associated with an increase in bone-specific alkaline phosphatase, a marker of bone formation; and a decrease in urine N-telopeptide, a marker of bone resorption.
Incidence of serious adverse events did not differ between the 2 groups. Among those women who continued treatment for 24 months, headaches were reported by 40 (35 percent) in nitroglycerin and 6 (5.4 percent) in placebo groups during the first month, decreasing substantially after 12 months.
"In conclusion, daily administration of nitroglycerin ointment increases bone formation and decreases bone resorption; thereby, substantially improving BMD, bone structure, and indices of bone strength at least as much as existing treatments. Together, these findings suggest that daily nitroglycerin may reduce the risk of vertebral and non-vertebral fractures. Furthermore, nitrates have a potential advantage of easy administration as an ointment, patch, or pill and wide availability of generic preparations. The efficacy of nitrates for reducing risk of fracture should be tested in a larger randomized controlled trial," the authors conclude.
(JAMA. 2011;305800-807. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Is Nitroglycerin a Novel and Inexpensive Treatment for Osteoporosis?
Sundeep Khosla, M.D., of Mayo Clinic, Rochester, Minn., writes in an accompanying editorial that although this study was underpowered to assess fracture risk, it should set the stage for an adequately powered, larger study using nitroglycerin ointment with fracture as an outcome.
"If such a study demonstrates efficacy for reducing fractures, clinicians would have a novel and inexpensive therapy for osteoporosis. The findings of the current study also should prompt development of additional nitric oxide donors with greater skeletal efficacy and a better adverse effect profile, particularly with regard to headaches."
(JAMA. 2011;305826-827. Available pre-embargo to the media at www.jamamedia.org)
Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.
To contact Sophie A. Jamal, M.D., Ph.D., call Jodi Salem at 416-323-6400, ext. 4054 or email firstname.lastname@example.org. To contact editorial author Sundeep Khosla, M.D., call Bob Nellis at 507-284-5005 or email Nellis.Robert@mayo.edu.
For More Information: Contact the JAMA/Archives Media Relations Department at 312-464-JAMA or email: email@example.com.